[go: up one dir, main page]

WO2003045428A3 - Verwendung einer technisch veränderten zelle als vakzine zur behandlung einer tumorerkrankung - Google Patents

Verwendung einer technisch veränderten zelle als vakzine zur behandlung einer tumorerkrankung Download PDF

Info

Publication number
WO2003045428A3
WO2003045428A3 PCT/EP2002/013531 EP0213531W WO03045428A3 WO 2003045428 A3 WO2003045428 A3 WO 2003045428A3 EP 0213531 W EP0213531 W EP 0213531W WO 03045428 A3 WO03045428 A3 WO 03045428A3
Authority
WO
WIPO (PCT)
Prior art keywords
modified cell
vaccine
technically modified
tumoral disease
disease
Prior art date
Application number
PCT/EP2002/013531
Other languages
English (en)
French (fr)
Other versions
WO2003045428A2 (de
Inventor
John Nieland
Claudia Breidenstein
Adelheid Dinkel
Ute Sartorius
Original Assignee
Medigene Ag
John Nieland
Claudia Breidenstein
Adelheid Dinkel
Ute Sartorius
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medigene Ag, John Nieland, Claudia Breidenstein, Adelheid Dinkel, Ute Sartorius filed Critical Medigene Ag
Priority to AU2002356763A priority Critical patent/AU2002356763A1/en
Publication of WO2003045428A2 publication Critical patent/WO2003045428A2/de
Publication of WO2003045428A3 publication Critical patent/WO2003045428A3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A61K39/001151—Apoptosis related proteins, e.g. survivin or livin p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00118—Cancer antigens from embryonic or fetal origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001188—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001189—PRAME
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A61K39/001192—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Die Erfindung betrifft die Verwendung einer technisch veränderten Zelle zur Behandlung einer Tumorerkrankung, wobei die technisch veränderte Zelle nicht von der jeweiligen Tumorerkrankung abgeleitet wurde, sowie ein Arzneimittel zur Prophylaxe, Therapie und/oder sekundären Prophylaxe einer Tumorerkrankung enthaltend eine technisch veränderte Zelle.
PCT/EP2002/013531 2001-11-30 2002-11-29 Verwendung einer technisch veränderten zelle als vakzine zur behandlung einer tumorerkrankung WO2003045428A2 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002356763A AU2002356763A1 (en) 2001-11-30 2002-11-29 Use of a technically modified cell as a vaccine for treating tumoral disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33449101P 2001-11-30 2001-11-30
US60/334,491 2001-11-30

Publications (2)

Publication Number Publication Date
WO2003045428A2 WO2003045428A2 (de) 2003-06-05
WO2003045428A3 true WO2003045428A3 (de) 2003-12-18

Family

ID=23307453

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/013531 WO2003045428A2 (de) 2001-11-30 2002-11-29 Verwendung einer technisch veränderten zelle als vakzine zur behandlung einer tumorerkrankung

Country Status (2)

Country Link
AU (1) AU2002356763A1 (de)
WO (1) WO2003045428A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2502015A1 (en) 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. 5' cpg nucleic acids and methods of use
DE10339905B4 (de) * 2003-08-29 2009-04-23 Kist-Europe Forschungsgesellschaft Mbh Implantierbarer Mikrozellprozessor zur Krankheitsbehandlung
RU2354694C2 (ru) * 2003-12-30 2009-05-10 Мологен Аг Аллогенное противоопухолевое терапевтическое средство
CN103245787B (zh) * 2012-02-01 2016-01-20 浙江大学 一种肝癌衍生生长因子检测试剂盒的制备方法
US11185586B2 (en) 2016-11-22 2021-11-30 Alloplex Biotherapeutics, Inc. Allogeneic tumor cell vaccine
JP7629178B2 (ja) * 2016-11-22 2025-02-13 アロプレックス バイオセラピューティクス 同種異系腫瘍細胞ワクチン

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0904786A1 (de) * 1997-08-22 1999-03-31 Science Park Raf S.p.A. Tumor-Impfung durch Verwendung von mit Antigen transduzierten autologen Zellen

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0904786A1 (de) * 1997-08-22 1999-03-31 Science Park Raf S.p.A. Tumor-Impfung durch Verwendung von mit Antigen transduzierten autologen Zellen

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YONGHONG WAN ET AL: "DENDRITIC CELLS TRANSDUCED WITH AN ADENOVIRAL VECTOR ENCODING A MODEL TUMOR-ASSOCIATED ANTIGEN FOR TUMOR VACCINATION", HUMAN GENE THERAPY, XX, XX, vol. 8, no. 11, 20 July 1997 (1997-07-20), pages 1355 - 1363, XP000877349, ISSN: 1043-0342 *

Also Published As

Publication number Publication date
AU2002356763A1 (en) 2003-06-10
WO2003045428A2 (de) 2003-06-05

Similar Documents

Publication Publication Date Title
BG108443A (en) Substituted oxazoliidinones for combinational therapy
MY127290A (en) New use of flibanserin
MXPA03011515A (es) Nuevas composiciones de medicamentos sobre la base de agentes anticolinergicos, corticoesteroides y agentes betamimeticos.
WO2003009838A1 (fr) Utilisation de composes de stilbene dans la preparation de medicaments pour le traitement ou la prevention du diabete et des maladies associees au retrovirus
AP1782A (en) Use of compounds ?-D or ?-L nucleoside for treating hepatitis C virus.
TNSN04113A1 (en) 3-â-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF
WO2002074337A8 (en) Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases
MXPA02011288A (es) Tioacetamidas substituidas.
TW200510343A (en) Substituted dihydroquinazolines
MXPA04003796A (es) Tioacetamidas sustituidas.
WO2002079169A8 (en) Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
GB0020504D0 (en) Therapeutic method
WO2002011747A3 (en) Transglutaminase for inhibiting angiogenesis
UA72927C2 (uk) Композиція для лікування печінково-клітинного раку, що містить доцетаксель
WO2003045428A3 (de) Verwendung einer technisch veränderten zelle als vakzine zur behandlung einer tumorerkrankung
NZ528164A (en) Use of flumazenil to produce a medicament for the treatment of cocaine dependency
IL161116A0 (en) Use of irbesartan for the preparation of medicaments that are used to prevent or treat pulmonary hypertension
DE50100833D1 (de) Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
EP1303300A4 (de) Zusammensetzungen und methoden zur behandlung von candidosen
PT1178819E (pt) Glutationa-redutase para a terapia e profilaxia da sida
WO2003056897A3 (en) Highly phosphorylated acid beta-glucocerebrosidase and methods of treating gaucher's disease
WO2002076930A3 (en) Substituted diarylureas as stimulators for fas-mediated apoptosis
IL174134A0 (en) Use of a protein in the preparation of a medicament for treatment of fibrotic diseases
ATE341323T1 (de) Verwendung von darifenacin zur behandlung des harndrangs
WO2004012732A3 (en) Use of a proteasome inhibitor in the treatment of endothelial dysfunction and/or in a low-dose proteasome inhibitor therapy

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP